Compare Sana Biotechnology Inc (SANA) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Trip.com Group Ltd — how do they compare? Sana Biotechnology Inc trades at $2.81 (market cap $836.71M), while Trip.com Group Ltd trades at $38.86 (market cap $23.75B). The key difference: Trip.com Group Ltd is far larger — about 28.4× Sana Biotechnology Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Trip.com Group Ltd for 79 Days on average.
| SANA | TCOM | |
|---|---|---|
Market Cap | $836.71M | $23.75B |
Volume | 4,507,444 | 2,089,737 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $78.96 |
52-Week Low | $2.68 | $37.96 |
Typical Hold Time | 23 Days | 79 Days |
Enterprise Value | $749.96M | $15.91B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Trip.com Group (TCOM) trades at $38.89, up 2.1% with mixed technical signals showing bearish moving averages but oversold RSI conditions. The company demonstrates strong fundamentals with revenue growing from $20.0B in 2022 to $62.4B in 2025, maintaining robust 36.9% net margins. Recent Q2 2026 earnings beat expectations at $1.07 per share versus $0.98 estimate, though regulatory headwinds from Chinese antitrust actions create uncertainty.
The stock presents a compelling value opportunity with low P/E of 7.34 and significant 46% upside to consensus price target of $56.64, supported by 70% analyst buy ratings. However, regulatory pressure on pricing algorithms and geopolitical risks require careful monitoring given the bearish technical setup and recent price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
